[Clinical, psychological and neurophysiological results of double-blind study on vincamine-cromesilate in patients with cerebro-vascular insufficiency (author's transl)].
In a long-term double-blind cross-over design 26 patients with amnestic syndrome due to cerebro-vascular insufficiency were submitted to vincamine-cromesilate (Vincaryl) and placebo treatment. The efficiency of vincamine was proved by mildly ameliorated psychometric patterns, biochemically by decreased cholesterol level and ophthalmodynamographically by slight increase of pulsation capacity. By means of EMG, ECG and EEG clinic side effects were excluded.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D004562:Electrocardiography; D004569:Electroencephalography; D004576:Electromyography; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014748:Vinca Alkaloids / Q000627:therapeutic use*; D014749:Vincamine / Q000009:adverse effects / Q000627:therapeutic use*
D014748:Vinca Alkaloids; D002784:Cholesterol; D014749:Vincamine
Klinische, psychologische und neurophysiologische Ergebnisse einer Doppelblindstudie mit Vincamin-cromesilat bei Patienten mit cerebraler Durchblutungsinsuffizienz.